Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Other financing activities (2020 - 2024)

Historic Other financing activities for Tarsus Pharmaceuticals (TARS) over the last 3 years, with Q3 2024 value amounting to $39000.0.

  • Tarsus Pharmaceuticals' Other financing activities changed N/A to $39000.0 in Q3 2024 from the same period last year, while for Sep 2025 it was $39000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $3.5 million for FY2024, which is N/A changed from last year.
  • Per Tarsus Pharmaceuticals' latest filing, its Other financing activities stood at $39000.0 for Q3 2024.
  • In the past 5 years, Tarsus Pharmaceuticals' Other financing activities registered a high of $2.1 million during Q4 2020, and its lowest value of $1000.0 during Q2 2020.
  • For the 3-year period, Tarsus Pharmaceuticals' Other financing activities averaged around $471000.0, with its median value being $60000.0 (2022).